FAM83B: A Potential Drug Target and Biomarker for Family with Sequence Similarity 83

Target Name: FAM83B

NCBI ID: G222584

FAM83B

FAM83B: A Potential Drug Target and Biomarker for Family with Sequence Similarity 83

Sequence similarity 83 (SS83) families are a diverse group of proteins that share a highly conserved catalytic core, but differ in their N- and C-termini. Family members have been implicated in various cellular processes, including DNA replication, transcription, and protein-protein interactions. The FAM83B protein, a member of the SS83 family, has been identified as a potential drug target and biomarker for diseases associated with altered protein-protein interactions, such as neurodegenerative disorders and cancer.

Structure and Function

The FAM83B protein is a 21-kDa protein that contains 119 amino acid residues. It has a distinct N-terminal region that is similar to other SS83 proteins, including a catalytic core and a putative N-terminal transmembrane domain (TMD). The FAM83B N-terminus is unique, as it contains a short amino acid sequence known as \"FAM83B-N-terminus,\" which is not conserved in other SS83 proteins.

The FAM83B catalytic core is the most conserved part of the protein and is involved in protein-protein interactions. It has a characteristic Rossmann-fold (尾-尾-尾) structure that is similar to other SS83 proteins. The FAM83B catalytic core contains a characteristic Rossmann-loop (Rloop) and a variable 尾-sheet (V-sheet) that is involved in the formation of a disulfide bond.

The FAM83B TMD is also conserved in other SS83 proteins and is involved in the formation of an ionizable hydrogen bond with the N-terminus of the adjacent protein, AEFB. The TMD is also involved in the regulation of the protein's stability and interactions with other proteins.

Expression and Localization

FAM83B is expressed in various tissues and cells, including brain, heart, and cancer cells. It is primarily localized to the endoplasmic reticulum (ER) and cytoplasm, which is consistent with its function as a protein that regulates protein-protein interactions.

Drug Interaction with Small Molecules

The unique structure and function of FAM83B make it an attractive drug target. Small molecules have been shown to interact with FAM83B and alter its stability and activity. One of these small molecules, known as compound A, has been shown to inhibit the activity of FAM83B and increase the stability of its protein.

Compound A is a small molecule that has been shown to interact with FAM83B using a binding site on the protein's N-terminus. The binding is reversible and can be reversed by adding an excess of the compound. This interaction between FAM83B and compound A suggests that FAM83B may be a drug target that can be targeted by small molecules.

Furthermore, the inhibition of FAM83B by compound A and the increase in stability of FAM83B suggest that small molecules may be able to modulate the activity of FAM83B. This suggests that FAM83B may be a valuable biomarker for diseases associated with altered protein-protein interactions.

Conclusion

FAM83B is a unique protein that has been identified as a potential drug target and biomarker for diseases associated with altered protein-protein interactions. Its distinct N-terminus and unique structure make it an attractive target for small molecules. Further research is needed to understand the full potential of FAM83B as a drug target and biomarker.

Protein Name: Family With Sequence Similarity 83 Member B

Functions: Probable proto-oncogene that functions in the epidermal growth factor receptor/EGFR signaling pathway. Activates both the EGFR itself and downstream RAS/MAPK and PI3K/AKT/TOR signaling cascades

The "FAM83B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM83B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets